NASDAQ •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 06/26/2026 15:06
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeNASDAQ
Market Capitalization54.49 mln
Float26.96 mln
Earnings Date08/19/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-8.74
Highly reliable
1-Year Forecast
3.17
Transformational upside
Relative Strength
94
/ 100
Top performer
Debt / Equity
0.00
Debt-free
ROE
-106
Deeply negative
Business Description
Talphera Inc. is a California-based pharmaceutical company focused on treatments used under direct medical supervision. Its leading program, Niyad, is a specialized formulation designed to prevent blood clotting during procedures that route blood outside the body. The company is also working on additional treatments targeting serious conditions such as viral infections, respiratory failure, and abnormal clotting disorders. Originally founded in 2005 as AcelRx Pharmaceuticals, it adopted its current name in early 2024.
